alpelisib

{
  "id": "MLC-T-ONC-000406",
  "term": "alpelisib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used with fulvestrant to treat postmenopausal women, and men, with hormone-receptor positive, HER2-negative breast cancer that is advanced or has spread and has a mutation (change) in the PIK3CA gene. It is used in patients whose cancer got worse during or after treatment with hormone therapy. It is also being studied in the treatment of other types of cancer. Alpelisib blocks certain proteins, which may help keep cancer cells from growing and may kill them. It is a type of kinase inhibitor. Also called Piqray.",
    "An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents."
  ],
  "synonyms": [
    "Piqray",
    "phosphoinositide 3-kinase inhibitor BYL719"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/alpelisib/"
}